PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Some net income increase while TRAW is negative at -169.35%. John Neff would see a short-term edge over the struggling competitor.
-22.93%
Both reduce yoy D&A, with TRAW at -8.33%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
18.38%
Deferred tax of 18.38% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Both cut yoy SBC, with TRAW at -2.93%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Slight usage while TRAW is negative at -967.96%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
A yoy AP increase while TRAW is negative at -189.42%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
300.21%
Some yoy usage while TRAW is negative at -281.85%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-40.28%
Negative yoy while TRAW is 106.02%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Some CFO growth while TRAW is negative at -29.95%. John Neff would note a short-term liquidity lead over the competitor.
19.38%
CapEx growth of 19.38% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth of 99.99% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
98.29%
We expand invests by 98.29% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
684.38%
We slightly raise equity while TRAW is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.